The BSE Sensex ended at 85,641.9, down 64.77 points (0.08%), after touching a record 86,159 early on. The Nifty50 closed at 26,175.75, slipping 27.2 points (0.1%), having earlier hit a lifetime peak of 26,325.8..
In the broader markets, the Nifty MidCap index ended flat, while the Nifty SmallCap index inched up 0.25%, showing that smaller stocks held stable even as frontline indices cooled off.
You may also like: Meesho IPO Date, Price, GMP, Details
Impact on the stock market
Sector-wise performance
Sector performance was mixed, with more red than green across the board.
Nifty Realty tumbled more than 1%, making it the worst-performing sector of the day. It was followed by declines in Healthcare, Pharma, Banking, Financial Services, FMCG, Media, Consumer Durables, and Oil & Gas.
Only a handful of sectors bucked the downward trend:
- Nifty Auto closed in the green
- Nifty Metal recorded gains
- Nifty IT also finished higher
| Sector/Index | Performance |
| IT & BPM sector | 0.39% |
| Healthcare sector | 0.55% |
| Oil & Gas sector | -0.69% |
| Real estate sector | -0.19% |
| PSU Bank in India | 0.25% |
Top gainers today
| Company | Share Price (in ₹) | Change % |
| Tata Motors | 363.80 | 1.96 |
| Bharat Electronics | 417.25 | 1.34 |
| Maruti Suzuki | 16,097.00 | 1.24 |
| HCL Technologies | 1,642.90 | 1.15 |
| Kotak Mah. Bank | 2,147.60 | 1.09 |
Top losers today
| Company | Share Price (in ₹) | Change % |
| Max Healthcare | 1,125.40 | -3.22 |
| Interglobe Aviation | 5,794.00 | -1.82 |
| Bajaj Finance | 1,021.10 | -1.58 |
| Sun Pharma.Inds. | 1,807.40 | -1.32 |
| Trent | 4,215.90 | -0.81 |
Market aftermath: Impact on stocks
Bajaj Finance and Bajaj Housing Finance: A strategic divestment move
One of the major corporate headlines of the day came from Bajaj Housing Finance, which announced that its promoter Bajaj Finance will sell up to 2% stake in the company. At current market prices, that stake is worth over ₹1,740 crore.
The divestment will help Bajaj Housing Finance meet mandatory minimum public shareholding norms, as Bajaj Finance currently owns 88.70% of the company.
Key highlights:
- Up to 16.66 crore shares will be sold between 2 December and February 2026
- Base price set at ₹95 per share, around 9% below the current market price
- The company currently commands a market cap of ₹87,148 crore
- Shares ended the day at ₹104.59, down slightly
While the stock has fallen over 30% from its listing price, it still trades 49% above its IPO price, reflecting continued investor interest since its blockbuster debut last year, where it listed at a 114% premium.
Silver surges to a record high: Why is the white metal shining?
One of the biggest stories across commodities was silver’s massive rally.
Silver futures skyrocketed to ₹1,78,649 per kg, rising ₹3,668 in a single day and marking a 13.5% surge (₹21,245) over just seven sessions.
Gold also joined the rally, with domestic prices climbing to ₹1,30,550 per 10 grams on the MCX.
What fuelled the surge?
- A weak US dollar
- Growing expectations of a US Federal Reserve rate cut, with markets pricing in an 87% probability of a 25 bps cut
- Safe-haven buying triggered by CME trading halts
- Strong global pricing, with Comex gold at USD 4,253.5/oz and Comex silver at USD 57.80/oz
Technical charts also turned bullish for silver, attracting traders and momentum buyers. The rupee’s weakness against the dollar added further support to domestic bullion prices.
Wockhardt soars 20% on historic US FDA approval
Shares of Wockhardt jumped 20%, hitting the upper circuit at ₹1,482, after the company achieved a landmark milestone:
The US FDA accepted its New Drug Application (NDA) for Zaynich, an antibiotic targeting complicated urinary tract infections (cUTIs) caused by multidrug-resistant gram-negative bacteria.
Why this matters:
- This is the first-ever NDA for a New Chemical Entity (NCE) from an Indian pharma company to be accepted by the US FDA
- Zaynich has earned Fast Track designation, meaning priority review
- The drug uses a novel β-lactam enhancer mechanism
- It has shown life-saving results through compassionate use in India and the US
The drug has been in development since 2011, and this approval marks a huge leap for India’s pharma innovation on the global stage.
Wockhardt’s stock has gained 14% in five days, reversing the declines seen in recent months.
Crude oil: Prices firm up on OPEC+ stance and supply risks
Oil prices moved higher as OPEC+ reaffirmed its decision to pause production hikes for the first quarter of 2026.
At 9:55 am:
- February Brent traded at $63.40 (up 1.64%)
- WTI January futures at $59.56 (up 1.73%)
- On MCX, December crude futures were at ₹5,342, up 0.34%
Key global triggers supporting prices:
- Attacks on Russian energy infrastructure, causing CPC terminal disruptions
- Kazakhstan redirecting exports due to mooring damages
- Rising global supply risks amid tensions between the US and Venezuela, threatening the supply of 800,000 barrels per day to global markets
Other commodities on NCDEX also saw movement:
- Turmeric futures: ₹14,860 (up 0.98%)
- Jeera futures: ₹22,100 (down 0.47%)
- Natural gas futures: ₹433.10 (up 1.74%)
Conclusion
Monday’s market may have closed flat, but the day was far from dull. From the Sensex hitting record highs to silver entering a full-throttle rally, from a landmark FDA approval to strategic divestments and rising crude oil prices — the day was packed with market-moving developments.
Even when benchmark indices move sideways, individual stories continue to create winners, losers, and opportunities for investors. As global uncertainties loom and commodities heat up, the coming sessions promise more action, especially in metals, pharma, and oil-linked sectors.
For more stock market insights, check out the StockGro blog.
